Market Cap 48.31M
Revenue (ttm) 0.00
Net Income (ttm) -22.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 253,400
Avg Vol 2,334,122
Day's Range N/A - N/A
Shares Out 16.05M
Stochastic %K 50%
Beta -1.15
Analysts Strong Sell
Price Target $24.50

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle l...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 509 6897
Address:
2916 North Miami Avenue, Suite 1000, Miami, United States
cray1965
cray1965 Jun. 28 at 5:58 AM
$VERU My theory on Veru. https://cray2223.substack.com/p/8bd9fbe2-055d-4707-b0c9-a33b0b34eb84
2 · Reply
cray1965
cray1965 Jun. 28 at 12:37 AM
$VERU Lilly bought Versanis and Bimagrumab, an injectible muscle retention drug, for up to 1.9B in July 2023, 4 months before Zepbound was even approved. That year Lilly made about 175M with Zepbound. Lilly made 12B in GLPs in just the first quarter of 2026 and could earn as much as 65B in GLPs this year.
2 · Reply
Ray89c
Ray89c Jun. 26 at 9:01 PM
$VERU Buy and Hold - Chart is Bullish - Consolidation then next 3.55 and then 4.59
0 · Reply
mrkymrk
mrkymrk Jun. 26 at 4:55 PM
$VERU volume is GONE!!!
0 · Reply
Drummerarmstrong1
Drummerarmstrong1 Jun. 26 at 4:25 PM
$VERU About to explode to the upside
0 · Reply
Eaa125
Eaa125 Jun. 26 at 2:34 PM
Morning watchers: $KMRK $ILLR $VERU $LASE
0 · Reply
justFrog
justFrog Jun. 25 at 5:58 PM
We gotta bring some life back to the $MAJI $1.6 mil revenue, $600K market cap, 20 mil float. Cancer diagnostic kit on the way. The exosomes might regrow your hair. What's not to like?? $SPYR $PHCG $VERU $ZENA
0 · Reply
cray1965
cray1965 Jun. 25 at 6:31 AM
$VERU Beyond weight loss, GLPs are now being tested for indications like cardiovascular disease, sleep apnea, MASH, chronic kidney disease, Alzhieimers, addiction, Osteoarthritis. Many of these patients will not be obese, and even moderate weight loss, especially in older patients, could be damaging to muscle. A muscle retention supplement will be even more important in these cases.
0 · Reply
Ray89c
Ray89c Jun. 24 at 7:04 PM
$VERU dca done, got the price to 3.65 with 10k shares now. price is holding at 3 well . one good new or earnings goes back to 5
1 · Reply
GenralZod
GenralZod Jun. 24 at 12:44 PM
$VERU interesting that I still can not purchase online with Fidelity. So many shady tickers out there can be bought online all day. This one gets some backing from NOVO and still requires a phone call to an agent.
0 · Reply
Latest News on VERU
Veru pact with Novo ‘significant event,’ says Canaccord

2026-06-04T16:45:29.000Z - 24 days ago

Veru pact with Novo ‘significant event,’ says Canaccord

NVO


Veru announces clinical supply agreement with Novo Nordisk

2026-06-04T16:40:26.000Z - 24 days ago

Veru announces clinical supply agreement with Novo Nordisk

NVO


Veru price target lowered to $24 from $25 at Oppenheimer

2026-05-15T14:08:45.000Z - 6 weeks ago

Veru price target lowered to $24 from $25 at Oppenheimer


Veru Inc. Earnings Call Transcript: Q2 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Veru Inc. Earnings Call Transcript: Q2 2026


Veru Inc. Earnings release: Q2 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Veru Inc. Earnings release: Q2 2026


Veru Inc. Quarterly report: Q2 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Veru Inc. Quarterly report: Q2 2026


Veru files $200M mixed securities shelf

2026-04-07T20:25:46.000Z - 2 months ago

Veru files $200M mixed securities shelf


Veru files to sell 23.8M shares of common stock

2026-04-07T20:22:21.000Z - 2 months ago

Veru files to sell 23.8M shares of common stock


Veru Inc. Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Veru Inc. Registration statement: Registration filing


Veru Inc. Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 2 months ago

Veru Inc. Registration statement: Registration filing


Veru Inc. Earnings Call Transcript: Q1 2026

Feb 11, 2026, 8:00 AM EST - 4 months ago

Veru Inc. Earnings Call Transcript: Q1 2026


Veru Inc. Quarterly report: Q1 2026

Feb 11, 2026, 8:00 AM EST - 4 months ago

Veru Inc. Quarterly report: Q1 2026


Veru Inc. Earnings release: Q1 2026

Feb 11, 2026, 8:00 AM EST - 4 months ago

Veru Inc. Earnings release: Q1 2026


Veru Inc. Quarterly report: Q1 2026

Feb 11, 2026, 8:00 AM EST - 4 months ago

Veru Inc. Quarterly report: Q1 2026


Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2026, 7:00 AM EST - 5 months ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2026, 7:00 AM EST - 5 months ago

Veru Inc. Proxy statement: Proxy Filing


Veru initiated with a Buy at Canaccord

2025-12-18T11:11:56.000Z - 6 months ago

Veru initiated with a Buy at Canaccord


Veru Inc. Earnings Call Transcript: Q4 2025

Dec 17, 2025, 8:00 AM EST - 6 months ago

Veru Inc. Earnings Call Transcript: Q4 2025


Veru Inc. Annual report: Q4 2025

Dec 17, 2025, 8:00 AM EST - 6 months ago

Veru Inc. Annual report: Q4 2025


Veru Inc. Earnings release: Q4 2025

Dec 17, 2025, 8:00 AM EST - 6 months ago

Veru Inc. Earnings release: Q4 2025


Veru Inc. Slides: Investor presentation

Nov 19, 2025, 5:24 PM EST - 7 months ago

Veru Inc. Slides: Investor presentation


Veru to Present Two Abstracts at ObesityWeek 2025

Oct 31, 2025, 8:30 AM EDT - 8 months ago

Veru to Present Two Abstracts at ObesityWeek 2025


Veru announces pricing of $25M public offering

2025-10-30T12:26:38.000Z - 8 months ago

Veru announces pricing of $25M public offering


Veru Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 8 months ago

Veru Announces Proposed Public Offering


Veru Inc. Earnings Call Transcript: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Veru Inc. Earnings Call Transcript: Q3 2025


Veru Inc. Quarterly report: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Veru Inc. Quarterly report: Q3 2025


Veru Inc. Earnings release: Q3 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Veru Inc. Earnings release: Q3 2025


Veru trading halted, news pending

2025-08-08T23:50:15.000Z - 11 months ago

Veru trading halted, news pending


Veru Announces Reverse Stock Split

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Veru Announces Reverse Stock Split


Veru Inc. Proxy statement: Proxy Filing

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing


Veru to Participate in the Virtual BTIG Obesity Health Forum

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Veru to Participate in the Virtual BTIG Obesity Health Forum


Veru Inc. Proxy statement: Proxy Filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Proxy statement: Proxy Filing

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Proxy statement: Proxy Filing


Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 9:25 AM EDT - 1 year ago

Veru Participates in a Virtual Investor KOL Connect Segment


Veru Inc. Earnings Call Transcript: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings Call Transcript: Q2 2025


Veru Inc. Quarterly report: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Quarterly report: Q2 2025


Veru Inc. Earnings release: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Veru Inc. Earnings release: Q2 2025


Veru Inc. Earnings Call Transcript: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Earnings Call Transcript: Q1 2025


Veru Inc. Quarterly report: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Quarterly report: Q1 2025


Veru Inc. Earnings release: Q1 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Veru Inc. Earnings release: Q1 2025


Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Transcript: Study Result

Jan 26, 2025, 7:00 PM EST - 1 year ago

Veru Inc. Transcript: Study Result


Veru Inc. Press release: Study Result

Jan 26, 2025, 7:00 PM EST - 1 year ago

Veru Inc. Press release: Study Result


Veru Inc. Annual report: Q4 2024

Dec 16, 2024, 12:00 AM EST - 1 year ago

Veru Inc. Annual report: Q4 2024


Veru Inc. Earnings Call Transcript: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings Call Transcript: Q3 2024


Veru Inc. Quarterly report: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Quarterly report: Q3 2024


Veru Inc. Earnings release: Q3 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings release: Q3 2024


Veru Inc. Proxy statement: Proxy Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Proxy statement: Proxy Filing

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 11:00 AM EDT - 2 years ago

Veru Inc. Transcript: Jefferies Global Healthcare Conference


Veru to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the Jefferies Global Healthcare Conference


Veru Announces Steven B. Heymsfield M.D.

May 15, 2024, 8:30 AM EDT - 2 years ago

Veru Announces Steven B. Heymsfield M.D.


Veru Inc. Proxy statement: Proxy Filing

May 9, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Proxy statement: Proxy Filing

May 9, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing


Veru Inc. Earnings Call Transcript: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings Call Transcript: Q2 2024


Veru Inc. Quarterly report: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Quarterly report: Q2 2024


Veru Inc. Earnings release: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Earnings release: Q2 2024


Veru Inc. Slides: Q2 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Slides: Q2 2024


Veru to Present at the GLP-1 Based Therapeutics Summit

May 2, 2024, 8:30 AM EDT - 2 years ago

Veru to Present at the GLP-1 Based Therapeutics Summit


Veru Inc. Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing


Veru Reschedules Annual Meeting of Shareholders

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Veru Reschedules Annual Meeting of Shareholders


Veru Inc. Proxy statement: Proxy Filing

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Veru Inc. Proxy statement: Proxy Filing


cray1965
cray1965 Jun. 28 at 5:58 AM
$VERU My theory on Veru. https://cray2223.substack.com/p/8bd9fbe2-055d-4707-b0c9-a33b0b34eb84
2 · Reply
cray1965
cray1965 Jun. 28 at 12:37 AM
$VERU Lilly bought Versanis and Bimagrumab, an injectible muscle retention drug, for up to 1.9B in July 2023, 4 months before Zepbound was even approved. That year Lilly made about 175M with Zepbound. Lilly made 12B in GLPs in just the first quarter of 2026 and could earn as much as 65B in GLPs this year.
2 · Reply
Ray89c
Ray89c Jun. 26 at 9:01 PM
$VERU Buy and Hold - Chart is Bullish - Consolidation then next 3.55 and then 4.59
0 · Reply
mrkymrk
mrkymrk Jun. 26 at 4:55 PM
$VERU volume is GONE!!!
0 · Reply
Drummerarmstrong1
Drummerarmstrong1 Jun. 26 at 4:25 PM
$VERU About to explode to the upside
0 · Reply
Eaa125
Eaa125 Jun. 26 at 2:34 PM
Morning watchers: $KMRK $ILLR $VERU $LASE
0 · Reply
justFrog
justFrog Jun. 25 at 5:58 PM
We gotta bring some life back to the $MAJI $1.6 mil revenue, $600K market cap, 20 mil float. Cancer diagnostic kit on the way. The exosomes might regrow your hair. What's not to like?? $SPYR $PHCG $VERU $ZENA
0 · Reply
cray1965
cray1965 Jun. 25 at 6:31 AM
$VERU Beyond weight loss, GLPs are now being tested for indications like cardiovascular disease, sleep apnea, MASH, chronic kidney disease, Alzhieimers, addiction, Osteoarthritis. Many of these patients will not be obese, and even moderate weight loss, especially in older patients, could be damaging to muscle. A muscle retention supplement will be even more important in these cases.
0 · Reply
Ray89c
Ray89c Jun. 24 at 7:04 PM
$VERU dca done, got the price to 3.65 with 10k shares now. price is holding at 3 well . one good new or earnings goes back to 5
1 · Reply
GenralZod
GenralZod Jun. 24 at 12:44 PM
$VERU interesting that I still can not purchase online with Fidelity. So many shady tickers out there can be bought online all day. This one gets some backing from NOVO and still requires a phone call to an agent.
0 · Reply
EdwardTeach
EdwardTeach Jun. 24 at 12:30 PM
1 · Reply
cray1965
cray1965 Jun. 23 at 8:59 PM
$VERU @mrkymrk Looks like they are running a Phase 2 with Tirzepitide, since the other phase 2 was with Semaglutide. This is the general obesity one they kept active after cancelling the T2D one. https://clinicaltrials.gov/study/NCT06643728?term=lilly%20bimagrumab&rank=2&tab=study&a=11
1 · Reply
mrkymrk
mrkymrk Jun. 23 at 4:24 PM
$LLY $VERU $NVO why has Lilly not initiated a phase 3 trial for bimagrumab? They also halted the phase 2 for Nima in diabetes patients late last year. What’s in the works?
0 · Reply
mpired
mpired Jun. 23 at 8:55 AM
0 · Reply
DalvadorSali
DalvadorSali Jun. 18 at 12:26 PM
$VERU Red pre market thats more like it
0 · Reply
cray1965
cray1965 Jun. 18 at 4:54 AM
$VERU Despite the Novo agreement, Veru is actually a better fit with Lilly: Foundayo and Enobosarm are both small molecules, which makes potential co-form easier and allows Lilly to manufacture Enobosarm alongside Foundayo in it's existing(and expanding) factory build-out. Veru and LIlly had a previous oncology supply agreement and clinical trial collaboration(that Veru abruptly paused to run the Quality GLP trial), so Lilly knows the molecule well and could also potentially pick the oncology trial back up for another revenue stream. Veru also has Sabizabulin which they are positioning as an anti-inflammatory drug for cardiovascular disease, a category Lilly is moving into.
0 · Reply
mrkymrk
mrkymrk Jun. 17 at 5:55 PM
$VERU why is this now pinned to $3??
1 · Reply
DalvadorSali
DalvadorSali Jun. 17 at 4:51 PM
$VERU Trapped in this trash ticker
2 · Reply
DalvadorSali
DalvadorSali Jun. 17 at 2:39 PM
$VERU Do something holy Jesus
0 · Reply
Eaa125
Eaa125 Jun. 17 at 2:25 PM
Morning watchers: $KMRK $VERU $KIDZ $GPUS
0 · Reply
DalvadorSali
DalvadorSali Jun. 17 at 12:43 PM
$VERU More red - go figure
0 · Reply
cray1965
cray1965 Jun. 16 at 9:57 PM
$VERU Experts are predicting the GLP market will be 150B by 2030. I think they're way off. Novo and Lilly combined made around 20B in Q1 of 2026 on GLP. That is just the first three months of Novo oral launch and before Lilly launched Foundayo, and before Medicare expansion and international is ramping up faster with the better oral logistics. Novo and Lilly combined will make $100B in GLP this year. By 2030 the GLP market will be closer to $300B/year. So- Novo and Lilly- pay a couple of Bs for Veru. It will be the best deal you ever made.
0 · Reply